Day: January 19, 2021

WESTFORD, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) was recognized by the Associated Industries of Massachusetts (AIM) for excellence in environmental stewardship, promotion of social well-being, and contributions to economic prosperity. The annual award distinguishes organizations that transparently manage their corporate social responsibilities while being held accountable to its stakeholders.“We are pleased to be recognized for our corporate sustainability efforts,” said Jeffrey L. Powell, president and chief executive officer of Kadant. “Kadant plays a critical role in the industrial supply chain by offering products and solutions that reduce the utilization of natural resources, increase productivity, and minimize energy consumption. Sustainability is central to who we are as a company. We are proud to...

WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) — Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the most recent hiring related to the continued expansion of the Company’s pathology service offerings through ongoing investment and key hires. Effective January 18, 2021, Adam Aulbach, DVM, DACVP, joined the Company as Director, Clinical Pathology.“We assess the needs of our clients on an ongoing basis and respond by enhancing our offerings,” said Dr. Stewart Jacobson, Senior Vice President, Pathology. “The ability to provide expertise in veterinary clinical pathology, and to integrate that expertise with our already strong anatomic pathology service, should create...

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) — Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quarter and full year ended December 31, 2020.Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019.“Our strong performance in 2020 demonstrated our ability to provide accessible healthcare to an increasing number of patients across the country,” stated Conversion Labs CEO, Justin Schreiber. “We ended the year exceptionally strong, with December revenues hitting a monthly record of $5.1 million, up 321% over December of last year. In fact, December 2020 alone eclipsed the whole of the...

Arrangement Reached with Fourth Utility DefendantCORSICANA, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) — Midwest Energy Emissions Corp. (OTCQB: MEEC) (“ME2C” or the “Company”), a leading environmental technologies firm, today announced the signing of an agreement to provide a large, North American utility (the “utility”) with a non-exclusive license to certain ME2C patents related to the Company’s two-part Sorbent Enhancement Additive (SEA®) process for mercury removal from coal-fired power plants, for use in connection with the utility’s coal-fired power plants.As a result of the agreement being announced today, ME2C has agreed to dismiss all claims brought against the utility in the patent litigation initiated by ME2C, and the utility has agreed to withdraw from petitions for Inter Partes Review which had been filed with the...

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wall Street Analyzer.  During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy™ to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions.  Mr. Joyce also reviews the Company’s 2021 clinical initiatives, the competitive landscape, public market comparables and the experience of the Sigyn team in developing first-in-industry therapies.The interview can be accessed in its entirety at: https://wallstreetanalyzer.com/2021/01/18/sigyn-therapeutics-inc-otcmarkets-sigy/About Sigyn TherapeuticsSigyn Therapeutics™ is a...

Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) for the eradication of H. pylori infection. Phathom continues to expect topline results from the study in the second quarter of 2021.PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients...

PASADENA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) — General Finance Corporation (NASDAQ:GFN), a leading specialty rental services company offering portable storage, modular space and liquid containment solutions (the “Company”), will announce its financial results for the second quarter ended December 31, 2020 of fiscal year 2021 before the U.S. market opens on Monday, February 8, 2021.Management will host a conference call the same day at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) to discuss the Company’s operating results. The conference call number for U.S. participants is (866) 901-5096 and the conference call number for participants outside the U.S. is (706) 643-3717. The conference ID number for both conference call numbers is 1605269. Additionally, interested parties can listen to a live webcast of the call in the “Investor...

Digital Forms and K12Docs Advisory Group Increase Platform Value and K-12 Market InsightCOLUMBUS, Ohio, Jan. 19, 2021 (GLOBE NEWSWIRE) — Intellinetics, Inc., (OTCQB: INLX) a cloud-based document solutions provider, announced today that the company is expanding its partnership with Software Unlimited Inc. (SUI) to add integrated electronic forms allowing K-12 school districts an easy, affordable option to create mobile forms and automated workflows. SUI is a major software developer and provider of solutions for the K-12 market, and from that partnership Intellinetics’ footprint has grown to supporting over 1.5 million students across 16 states in 235 schools and districts, a 432% increase from a year ago.IntelliCloud™, Intellinetics’ flagship platform, is seamlessly integrated into SUI’s School Accounting System. Marketed as K12Docs,...

DALLAS, Jan. 19, 2021 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest”) (Nasdaq:CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today that it supported O2 Investment Partners, LLC’s (“O2”) significant investment in Flip Electronics, LLC (“Flip” or the “Company”) with a first lien term loan and equity co-investment. Capital Southwest serves as the term loan agent on the credit facility. PNC Bank is a first-out lender in the term loan and provided a revolving credit facility. Main Street Capital Corporation (NYSE: MAIN) is also a last-out lender in the term loan.“We are excited to partner with O2 on its investment in Flip,” said Ryan Kelly, Principal of Capital Southwest. “Flip’s...

Frederick, Maryland, Jan. 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK:BIEL) is pleased to report that Q4 revenue for 2020 exceeded $519,000, representing an increase of 241% when compared to Q3 revenue in 2020 ($151,956). Correspondingly, Q4 2020 revenue represents an increase of 233% when compared to the cumulative revenue of Q1 and Q2 in 2020 ($155,818). As of today, the Company has $554,074 in deferred revenue remaining on the books, at least half of which is scheduled to ship in Q1 of 2021.Richard Staelin, Ph.D., Chairman of the Board, said, “We believe this increase in both revenue and deferred revenue is a strong signal that the firm is moving in the right direction.”  He attributes this robust growth to the firm’s unique portfolio of products and the management’s decision to prioritize...